Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
E: investor.relations@sanofi.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,913.90 | 352.20 | 4.66% |
| CAC 40 | 7,366.68 | 503.66 | 7.34% |
| DAX 40 | 21,135.44 | 1,464.56 | 7.45% |
| Dow JONES (US) | 40,205.73 | 340.20 | -0.84% |
| FTSE 100 | 8,096.05 | 416.57 | 5.42% |
| HKSE | 20,748.95 | 484.46 | 2.39% |
| NASDAQ | 17,124.97 | 574.37 | 3.47% |
| Nikkei 225 | 34,609.00 | 2,894.97 | 9.13% |
| NZX 50 Index | 12,201.43 | 394.88 | 3.34% |
| S&P 500 | 5,381.00 | 398.23 | 7.99% |
| S&P/ASX 200 | 7,709.60 | 334.60 | 4.54% |
| SSE Composite Index | 3,223.64 | 36.83 | 1.16% |